Skip to Content

News & Events

Access our recent and archived press releases. This section also provides a calendar of upcoming events and presentations.

Our Newsroom

Investors

Our investor relations portal provides access to our financial information, filings, investor presentations and stock information.

Investor Tools

Our Products

We develop high-potential molecules that have compelling safety and promising efficacy data and transform them into proprietary products that enable significant advances in patient care and outcomes.

Our Products

Pipeline and Therapy Development

VIVUS is dedicated to meeting the needs and improving quality of life of patients with serious medical conditions and life-limiting diseases.

Pulmonary Arterial Hypertension (PAH)

PAH is a degenerative and life-threatening disease that makes it difficult for the heart to pump blood to the lungs to be oxygenated and may ultimately lead to heart failure. Current PAH treatment options only address the symptoms, slowing but not preventing disease progression. New therapies that address the underlying cause of disease are urgently needed.

Learn More

Latest Press Releases

Other Links & Resources

You are about to leave the VIVUS Inc. website

Links to third-party websites on VIVUS.com are provided solely for your convenience.

VIVUS Inc. does not control the content contained on any third-party website linked from this website. Activities on third-party websites will be governed by the policies and terms of use of those third parties.